Literature DB >> 18771083

VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.

Shu-Fang Jia1, Hui Guan, Xiaoping Duan, Eugenie S Kleinerman.   

Abstract

Our previous studies showed that Fas expression correlates inversely with the metastatic potential of osteosarcoma (OS) cells and that the manipulation of Fas expression alters the lung metastatic phenotype. However, the role of VEGF in the growth and metastases of OS is unclear. The purpose of this study was to determine whether altering VEGF expression affects lung metastatic potential. LM7 metastatic OS cells were transfected with a small interfering RNA targeting human VEGF165 (LM7/siVEGF165) or a pcDNA4 plasmid expressing human VEGF165 (LM7/VEGF). We confirmed that VEGF165 expression was decreased in LM7/siVEGF165 cells and was increased in LM7/VEGF clones compared with control transfected clones. Fas expression was not altered in these transfected clones. We also transfected LM7 cells with Fas (LM7/Fas) or Fas together with VEGF165 (LM7/Fas/VEGF) to determine whether the overexpression of VEGF165 could enhance the metastatic potential of LM7 OS cells with high Fas expression (Fas(+)). LM7/siVEGF165 and LM7/Fas cells showed decreased lung metastatic potential. In addition, the overexpression of VEGF had no effect on the ability of LM7/Fas cells to form lung metastases. We therefore concluded that VEGF165 is critical to lung metastatic potential but is not sufficient to allow Fas(+) OS cells to survive in the Fas ligand lung microenvironment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771083      PMCID: PMC2562636     

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  25 in total

1.  Metastasis-associated differences in gene expression in a murine model of osteosarcoma.

Authors:  C Khanna; J Khan; P Nguyen; J Prehn; J Caylor; C Yeung; J Trepel; P Meltzer; L Helman
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

2.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

3.  Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.

Authors:  F Eilber; A Giuliano; J Eckardt; K Patterson; S Moseley; J Goodnight
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

4.  Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study.

Authors:  A M Goorin; J J Shuster; A Baker; M E Horowitz; W H Meyer; M P Link
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

5.  Eradication of osteosarcoma lung metastasis using intranasal gemcitabine.

Authors:  Shu-Fang Jia; Laura L Worth; Mustofo Turan; Xiao-ping Duan Xp; Eugenie S Kleinerman
Journal:  Anticancer Drugs       Date:  2002-02       Impact factor: 2.248

6.  Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium.

Authors:  P Möller; K Koretz; F Leithäuser; S Brüderlein; C Henne; A Quentmeier; P H Krammer
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

7.  Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases.

Authors:  Shu-Fang Jia; Laura L Worth; Charles L Densmore; Bo Xu; Xiaoping Duan; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

8.  Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.

Authors:  K P Claffey; L F Brown; L F del Aguila; K Tognazzi; K T Yeo; E J Manseau; H F Dvorak
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

Review 9.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

Review 10.  Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

Authors:  Nishan H Fernando; Herbert I Hurwitz
Journal:  Semin Oncol       Date:  2003-06       Impact factor: 4.929

View more
  6 in total

Review 1.  Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

Authors:  Julia Glade Bender; Darrell J Yamashiro; Elizabeth Fox
Journal:  Oncologist       Date:  2011-10-31

2.  Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.

Authors:  Luciana M Gutiérrez; Matías Valenzuela Alvarez; Yuanzheng Yang; Fiorella Spinelli; María José Cantero; Laura Alaniz; Mariana G García; Eugenie S Kleinerman; Alejandro Correa; Marcela F Bolontrade
Journal:  Apoptosis       Date:  2021-05-22       Impact factor: 4.677

3.  Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.

Authors:  Ming-Szu Hung; I-Chuan Chen; Paul-Yann Lin; Jr-Hau Lung; Ya-Chin Li; Yu-Ching Lin; Cheng-Ta Yang; Ying-Huang Tsai
Journal:  Oncol Lett       Date:  2016-10-18       Impact factor: 2.967

4.  CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model.

Authors:  Lisa Mayr; Christine Pirker; Daniela Lötsch; Sushilla Van Schoonhoven; Reinhard Windhager; Bernhard Englinger; Walter Berger; Bernd Kubista
Journal:  Oncotarget       Date:  2017-12-09

5.  223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy.

Authors:  Pete M Anderson; Jacob Scott; Shireen Parsai; Stacey Zahler; Sarah Worley; Sankaran Shrikanthan; Vivek Subbiah; Erin Murphy
Journal:  ESMO Open       Date:  2020-04

Review 6.  Osteosarcoma and Metastasis.

Authors:  Gaohong Sheng; Yuan Gao; Yong Yang; Hua Wu
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.